Hikma Taps Celltrion Again To Bring In MENA Stelara Biosimilar
Adalimumab Biosimilar Only Recently Added To Long-Term Partnership
Executive Summary
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.
You may also be interested in...
Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.
Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.
Alvotech Sets Sights On Stelara Submission By Close Of 2022
Tipped to bring in revenues from its proposed Stelara biosimilar of $600m in 2027, Alvotech has confirmed plans for a potentially landmark filing with major regulators by the end of the year.